Effect of Xuefu Zhuyu Capsule (血府逐瘀胶囊) on the Symptoms and Signs and Health-related Quality of Life in the Unstable Angina Patients with Blood-stasis Syndrome after Percutaneous Coronary Intervention: A Randomized Controlled Trial  

作　　者：褚福永 王阶 姚魁武 李志忠 

机构地区：[1]Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences [2]Rescue Center of Emergency, Anzhen Hospital, China Capital University of Medical Science

出　　处：《Chinese Journal of Integrative Medicine》2010年第5期399-405,共7页中国结合医学杂志（英文版）

基　　金：Supported by the National Natural Science Foundation of China(No. 90709048)

摘　　要：Objective： Compared with Shengmai Capsule （生脉胶囊, SM）, the study was conducted to evaluate the efficacy and safety of Xuefu Zhuyu Capsule （血府逐瘀胶囊, XFZY） on the symptoms and signs and health-related quality of life （HR-QOL） in the unstable angina （UA） patients with blood-stasis syndrome （BSS） after percutaneous coronary intervention （PCI）. Methods： A randomized, double-blinded, doubledummy, and placebo-controlled trial was applied. Ninety patients, diagnosed as UA and BSS after successful PCI, were enrolled and equally randomized into three groups, XFZY group, SM group, and placebo group, and administered with the corresponding medications respectively for four weeks. The clinical symptoms and signs （CSS）, electrocardiography （ECG）, and BSS scores were recorded and compared among groups during and after the treatment. Short-form 36 （SF-36） and Seattle Angina Questionnaire （SAQ） were applied to assess the HR-QOL in each group before and after the treatment. Safety indexes （blood routine and liver and kidney function tests） were also examined at the beginning and after the treatment. Results： Eighty-six patients completed the whole study. After the treatment, the total effective rates of the XFZY group in ameliorating CSS and ECG were 76.7% and 60.0%, respectively, which were obviously higher than those in SM （CSS： 53.3%; ECG： 36.7%） and the placebo （CSS： 43.3%; ECG： 30.0%） groups. After one week＇s treatment, BSS scores slightly decreased in each group, but no significant differences were found among three groups （P0.05）. After four weeks＇ treatment, BSS scores in the XFZY group decreased to a lower level compared with SM （P0.05） and the placebo （P0.01） groups. After the treatment, the efficacy of XFZY group in improving body pain （BP）, general health （GH）, vitality （VT）, society functioning （SF）, role emotional （RE）, angina stability （AS）, angina frequency （AF）, and treatment satisfactionObjective： Compared with Shengmai Capsule （生脉胶囊, SM）, the study was conducted to evaluate the efficacy and safety of Xuefu Zhuyu Capsule （血府逐瘀胶囊, XFZY） on the symptoms and signs and health-related quality of life （HR-QOL） in the unstable angina （UA） patients with blood-stasis syndrome （BSS） after percutaneous coronary intervention （PCI）. Methods： A randomized, double-blinded, doubledummy, and placebo-controlled trial was applied. Ninety patients, diagnosed as UA and BSS after successful PCI, were enrolled and equally randomized into three groups, XFZY group, SM group, and placebo group, and administered with the corresponding medications respectively for four weeks. The clinical symptoms and signs （CSS）, electrocardiography （ECG）, and BSS scores were recorded and compared among groups during and after the treatment. Short-form 36 （SF-36） and Seattle Angina Questionnaire （SAQ） were applied to assess the HR-QOL in each group before and after the treatment. Safety indexes （blood routine and liver and kidney function tests） were also examined at the beginning and after the treatment. Results： Eighty-six patients completed the whole study. After the treatment, the total effective rates of the XFZY group in ameliorating CSS and ECG were 76.7% and 60.0%, respectively, which were obviously higher than those in SM （CSS： 53.3%; ECG： 36.7%） and the placebo （CSS： 43.3%; ECG： 30.0%） groups. After one week＇s treatment, BSS scores slightly decreased in each group, but no significant differences were found among three groups （P0.05）. After four weeks＇ treatment, BSS scores in the XFZY group decreased to a lower level compared with SM （P0.05） and the placebo （P0.01） groups. After the treatment, the efficacy of XFZY group in improving body pain （BP）, general health （GH）, vitality （VT）, society functioning （SF）, role emotional （RE）, angina stability （AS）, angina frequency （AF）, and treatment satisfaction

关 键 词：Xuefu Zhuyu Capsule unstable angina percutaneous coronary intervention DOUBLE-BLIND double-dummy 

分 类 号：R259[医药卫生—中西医结合]